{"brief_title": "Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.", "brief_summary": "The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.", "condition": ["Breast Cancer"], "intervention_type": ["Drug"], "intervention_name": ["Fulvestrant"], "description": ["intramuscular injection"], "arm_group_label": ["1", "2"], "other_name": ["Faslodex", "ZD9238"], "criteria": "Inclusion Criteria: - Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor - Requiring hormonal treatment - Postmenopausal women defined as a woman who has stopped having menstrual periods - Evidence of positive estrogen receptor hormone sensitivity - Written informed consent to participate in the trial Exclusion Criteria: - Treatment with an investigational or non-approved drug within one month - An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures - A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor oil) - Treatment with more than one regimen of chemotherapy for advanced breast cancer - Treatment with more than one regimen of hormonal treatment for advanced breast cancer", "gender": "Female", "minimum_age": "45 Years", "maximum_age": "130 Years", "healthy_volunteers": "No", "keyword": "Metastatic Breast Cancer", "mesh_term": ["Breast Neoplasms", "Fulvestrant", "Estradiol", "Estrogens"], "id": "NCT00099437"}